Volume 6, Number 2
Monday, January 16, 2006



In this issue: (click heading to view article)
Dietary Intake of Antioxidants and Risk of AMD
Are Diabetes and Keratoconus Associated?
Bone Marrow-Derived Cells in Normal Human Corneal Stroma
Briefly











Dietary Intake of Antioxidants and Risk of AMD

Recently, high-dose supplementation with beta carotene, vitamins C and E and zinc has been shown to slow the progression of age-related macular degeneration (AMD). Researchers from the Netherlands initiated a population-based cohort study to investigate whether regular dietary intake of antioxidants is associated with a lower risk of incident AMD.

Dietary intake was assessed at baseline in the Rotterdam Study (1990-1993) using a semiquantitative food frequency questionnaire. Investigators determined incident AMD, defined as soft distinct drusen with pigment alterations, indistinct or reticular drusen, geographic atrophy or choroidal neovascularization, until final follow-up in 2004 by grading fundus color transparencies in a masked technique according to the International Classification and Grading System.

Of 5,836 persons at risk of AMD at baseline, 4,765 had reliable dietary data and 4,170 participated in the follow-up. Subjects in the study were drawn from all inhabitants aged 55 years or older in a middle-class suburb of Rotterdam, the Netherlands.

Incident AMD occurred in 560 participants after a mean follow-up of 8.0 years (range, 0.3 to 13.9 years). Dietary intake of vitamin E and zinc was inversely associated with incident AMD. The hazard ratio (HR) per standard deviation increase of intake for vitamin E was 0.92 (95 percent CI, 0.84 to 1.00); for zinc it was 0.91 (95 percent CI, 0.83 to 0.98). An above-median intake of all four nutrients, beta carotene, vitamin C, vitamin E and zinc was associated with a 35 percent reduced risk (HR, 0.65; 95 percent CI, 0.46 to 0.92) of AMD. Exclusion of supplement users did not affect the results. The authors concluded that a high dietary intake of beta carotene, vitamins C and E and zinc is associated with a substantially reduced risk of AMD in older people.

SOURCE: van Leeuwen R, Boekhoorn S, Vingerling JR, et al. Dietary intake of antioxidants and risk of age-related macular degeneration. JAMA 2005;294(24):3101-7.
Table of Contents











Are Diabetes and Keratoconus Associated?

The Wilmer Eye Institute and Department of Ophthalmology at Johns Hopkins University School of Medicine conducted a retrospective, comparative study to determine whether there is an association between diabetes mellitus (DM) and keratoconus.

The study compared the proportion of keratoconus patients with those with DM versus the proportion of overall patients with DM, and included a retrospective cross-sectional study of a cohort consisting of all diabetic keratoconus patients and randomly selected keratoconus patients without DM seen at the Wilmer Eye Institute from January 1, 1995, through March 18, 2004. Researchers reviewed billing data and clinic charts; eligibility criteria for the cross-sectional study were one or more clinic visits, lack of other eye pathologic features (excluding cataract and diabetic retinopathy) and absence of bilateral penetrating keratoplasty (PK) at presentation. Application of novel keratoconus severity index was based on best-corrected visual acuity (BCVA) in the better eye at last visit and defined as: Grade 1 (least severe), spectacle wear with BCVA of 20/40 or better; Grade 2 (intermediate), spectacle wear with BCVA worse than 20/40 or rigid gas permeable lens wear; Grade 3 (most severe), PK.

Results showed no difference in the prevalence of DM in keratoconus patients and those without keratoconus, and no difference in the prevalence of DM in keratoconus patients and those without keratoconus undergoing PK. However, they did suggest a negative association between DM and severity of keratoconus (Fisher exact test). The odds of being in the most severe group as opposed to the least severe group were lower in DM patients than in those without DM (odds ratio [OR] = 0.20; 95 percent confidence interval [CI], 0.05 to 0.70). Compared with those without DM, DM patients also had lower odds of being in the intermediate group than in the least severe group (OR = 0.25; 95 percent CI, 0.08 to 0.80). After adjustment for age, gender and race, these differences remained statistically significant. Investigators concluded that DM is not associated with a diagnosis of keratoconus, but having DM decreases the odds of having more severe keratoconus.

SOURCE: Kuo IC, Broman A, Pirouzmanesh A, Melia M. Is there an association between diabetes and keratoconus? Ophthalmol. 2005;Dec 17 [Epub ahead of print].
Table of Contents










Bone Marrow-Derived Cells in Normal Human Corneal Stroma

Japanese researchers have discovered bone marrow-derived monocyte lineage cells in the anterior and peripheral posterior stroma of normal human corneas.

The investigators examined 34 corneas from donors aged 56 to 71 years immunohistochemically by fluorescent microscopy. They separated CD45-positive and -negative cells from collagenase-digested stroma by magnetic beads and analyzed the expression of toll-like receptor 4. (CD45, also known as the leukocyte common antigen, is present on all human cells involved in production and development of blood, except erythroid cells, platelets and their precursor cells. The CD45 molecule is required for T-cell and B-cell activation.)

CD45-positive cells were mainly found in the anterior stroma of the central and paracentral cornea, as well as all stromal layers of the peripheral cornea. These cells uniformly expressed CD11b, CD11c, CD14 and HLA-DR antigen but not CD3, CD19, CD56 or CD66, indicative of bone marrow-derived monocyte lineage cells, which can include monocytes, macrophages or dendritic cells. CD45-positive cells isolated with magnetic beads accounted for 6 percent of total stromal cells. Stromal CD45-positive cells, but not CD45-negative cells, expressed toll-like receptor 4 by flow cytometry and reverse-transcriptase polymerase chain reaction. The authors believe that the bone marrow-derived cells may play a role in the innate and adaptive immune responses in the human cornea.

SOURCE: Yamagami S, Ebihara N, Usui T, et al. Bone marrow-derived cells in normal human corneal stroma. Arch Ophthalmol. 2006;124:62-9.
Table of Contents

 




BRIEFLY
  • BIOMARKER FOR AMD FOUND. Patients with elevated blood levels of homocysteine, an amino acid that is a known biomarker for cardiovascular disease, may also be at an increased risk of developing age-related macular degeneration (AMD), according to a study in the January 2006 issue of the American Journal of Ophthalmology. The study, conducted at the Massachusetts Eye and Ear Infirmary and the Devers Eye Institute in Portland, OR, measured the fasting plasma homocysteine levels of 934 people, 547 with AMD and 387 controls, who were participants in an ancillary study of the Age-Related Eye Disease Study. Results suggested that elevated homocysteine in the blood may be another biomarker for increased risk of AMD. Because homocysteine can be reduced by dietary intake of vitamins B6, B12 and folate, the authors of the study believe that the relationship between the amino acid and AMD merits further study.
  • NEUROTECH BEGINS PHASE II CLINICAL TRIAL OF DRY AMD TREATMENT. Neurotech is initiating a Phase II clinical trial of NT-501, the company"s Encapsulated Cell Technology (ECT) product for the treatment of visual loss associated with dry age related macular degeneration (AMD). The treatment is an intraocular polymer implant containing human retinal epithelial cells genetically modified to secrete Ciliary Neurotrophic Factor (CNTF). The implant is designed to continuously release CNTF directly into the diseased retinal tissue for sustained periods. The randomized, double-masked, sham-controlled dose ranging study, conducted at the National Eye Institute (NEI) in Bethesda, MD, will evaluate the efficacy and safety of the CNTF implant. An open-label Phase I clinical trial of the treatment was conducted in patients with retinitis pigmentosa (RP); results, which were presented in November 2005, confirmed that CNTF can be safely delivered into the vitreous of patients with RP. The implants were well tolerated by the RP patients, and some patients experienced improvement in their visual acuity score. For more information on Neurotech, go to www.neurotechusa.com.
  • NASCENT PHARMACEUTICALS REPORTS POSITIVE RESULTS FOR PHASE II DRY EYE TREATMENT. Nascent Pharmaceuticals has announced positive results of a 90-patient, 14-week Phase IIb clinical trial of iDESTRIN (NP50301), a topical ophthalmic therapeutic eye drop for treating Dry Eye Syndrome (DES) in postmenopausal women. The clinical trial was a randomized, vehicle controlled double-masked study, with 30 patients in each of three arms receiving either vehicle or one of two active doses; and enrolled patients with mild, moderate and severe disease. In patients with moderate-to-severe disease, (about half those enrolled), researchers noted a significant improvement in the high-dose group for the main objective endpoint, the Schirmer"s Test, at eight weeks and 12 weeks, in both eyes versus vehicle--an improvement of more than 75 percent from baseline. This group also demonstrated a significant improvement at 12 weeks for two other objective endpoints: superficial punctuate keratopathy and corneal staining (p=0.045). In the moderate-to-severe group, a significant improvement was achieved in both active dose groups for the main subjective endpoint (foreign body sensation) at four weeks, as compared to vehicle in both eyes, and this improvement was maintained throughout the study. No drug-related serious adverse events were reported. For more information on Nascent Pharmaceuticals, go to www.nascentpharma.com.


Table of Contents



 Check Yearly. See Clearly. Open Your Eyes To the Opportunities.
It"s only been up and running a few short weeks. Yet, it"s already clear that the Check Yearly. See Clearly.(SM) marketing campaign is opening consumers" eyes to the benefits of regular eye exams. Call the Vision Council of America at 800-424-8422 today or visit checkyearly.com for your free promotional materials.